Online Activities

Connect & Knowledge-share with your Peers

Our regular Online Activities keep you connected to the conversation, through our Monthly Science Exchanges and Webinars from industry experts and cutting-edge solution providers.


Upcoming Activities

27/06/24, 9am PT | 12pm EST | 5pm BST | Sponsor Webinar

A New Golden Age for Target Identification: Accessing the Novel Druggable Space with Discovery Proteomics

Presented by Mo Jain, MD, PhD, Founder and CEO, Sapient and Jonathan Usuka, PhD, MBA Chief Business Officer, Sapient

Pharmaceutical drug development has traditionally focused on a limited number of well-characterized biological targets, with multiple companies developing drugs around the same proteins and pathways. Competitive crowding has created a race to compress time-to-market, prioritizing development execution over novel exploration.

Luckily, innovative new drug modalities are expanding the druggable space to disease-modifying proteins once considered too challenging to reach. This is ushering a new era for target identification, opening up new areas of the proteome for therapeutic targeting.

In this webinar, we will discuss how mass spectrometry-based discovery proteomics enables therapeutic developers to rapidly map this novel druggable space, measuring thousands of proteins and PTMs in the blood and tissue proteome with high analytical specificity. We will share how these analyses can lead developers to the most biologically interesting targets – not just the most popular – for novel discovery and greenfield development opportunities that can pave the way for new therapeutic breakthroughs.

You’ll learn about:

  • Trends that have led to intense competition around a small pool of protein targets
  • How innovative new drug modalities are significantly broadening the druggable space
  • Why mass spectrometry-based discovery proteomics is ideally suited for the new ‘golden era’ of target identification, supporting novel discovery of drug targets in the previously undruggable realms of the proteome
Register (Free)

Speaker Bio

Mo Jain, MD, PhD
Founder and CEO, Sapient

Dr. Jain is a physician-scientist with more than 20 years of expertise in physiology, biomedicine, engineering, computational biology, and mass spectrometry. Prior to founding Sapient, he formed and was director of Jain Laboratory at the University of California San Diego (UCSD). There he led a multi-disciplinary research team to develop next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) systems to probe dynamic biomarkers of health, disease, and drug response across population-scale human studies. Dr. Jain founded Sapient in 2021 as a spinout of Jain Laboratory to expand upon the mission of accelerating insight into human biology to advance precision drug development.

Dr. Jain obtained his MD and PhD from Boston University School of Medicine, and subsequently performed clinical residency and fellowship training in Internal Medicine, Cardiology, and Preventative Cardiology at Brigham and Women’s Hospital, Harvard Medical School. His postdoctoral work was performed at the Broad Institute and Massachusetts General Hospital in the HHMI laboratory.

Jonathan Usuka, PhD, MBA
Chief Business Officer, Sapient

Dr. Usuka has more than 25 years of experience in the pharmaceutical industry spanning both business and scientific leadership roles. He was previously Chief Strategy Officer at REALM IDx, where he led the creation and launch of integrated diagnostics in pharmaceutical services. Dr. Usuka was also a Senior Expert at McKinsey & Company, leading their Center for Analytics and Real-world Evidence. In that role he served pharmaceutical industry leaders in advancing their therapeutic pipelines through AI and supported M&A strategy for private equity investors in pharmaceutical services. He has additionally held senior positions at top pharmaceutical companies including as Director, R&D Informatics at Celgene and as Director, Global R&D Information at Roche. 

Dr. Usuka earned a PhD in Chemistry and was an NIH Fellow in Genetics at Stanford University’s School of Medicine, and holds an MBA in Finance from The Wharton School, University of Pennsylvania and a BA from Princeton University.

Planned for July 2024 | Science Exchange

The Challenges In Integrating AI Into Biomarker Research

• AI • Machine Learning & Computational Drug Design • Biomarker Technologies • Biomarkers for Drug Discovery & Development

Presented by Katrina Campbell, Professor in Food Security and Diagnostics, Queen's University Belfast

 •Biomarker specificity
• Regulatory hurdles
• Patient engagement

Register Interest
Planned for September 2024 | Science Exchange

Regulatory developments for biomarker research

• Diagnostics
  • IVDR regulations 

Register Interest
Planned for September 2024 | Science Exchange

Biomarkers Research For Neurodegenerative Diseases

• Biomarkers for Clinical Development • Biomarkers for Drug Discovery & Development • Neuroscience Discovery • Diagnostics

Presented by Giovanna Lalli, Director of Strategy & Operations, LifeArc

  • Prediction and diagnosis of neurodegenerative diseases
  • The use of liquid biomarkers neurodegenerative diseases
  • Overcoming translational barriers in biomarker research for Alzheimer's & MSD
  • Patient support & how diagnostic research can impact patients
Register Interest
Planned for October 2024 | Science Exchange

Multi- Omics Approaches To Biomarker Discovery

• Genomic Markers & Precision Medicine • Biomarkers for Drug Discovery & Development
  •  Preclinical Validation
  • Analytical and Clinical Validation
  • Regulatory Pathways
  •  Biomarker Identification
Register Interest
Planned for November 2024 | Science Exchange

The Use Of Liquid Biopsies For Early Diagnosis Of Cancer

• Biomarkers for Clinical Development • Biomarkers in Immuno-oncology • Genomic Markers & Precision Medicine
  • Explore the role of liquid biopsy in tailoring precision medicine approaches for individual cancer patients
  • Overcoming current challenges and limitations associated with biopsy techniques
  • Exploring tumor heterogeneity
Register Interest

You can catch up on our past Biomarkers webinar recordings on our Resources page.